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Objective: Adipocytokines have been reported to contribute to the pathogenesis of colorectal cancer
(CRC). The aim of this matched case-control study was to explore circulating novel adipocytokines, such
as serum visfatin, omentin-1 and vaspin levels in patients with CRC.
Method: Serum visfatin, omentin-1, and vaspin levels were measured in 69 subjects (39 patients with
colorectal cancer and 30 age- and sex-matched healthy controls) using enzyme-linked immunosorbent
assay (ELISA) methods.
Results: Compared with the controls, patients with CRC had signiﬁcantly higher circulating omentin-1
(203.23 vs 9.12 ng/ml, p < 0.0001) visfatin (4.03 vs 2.01 ng/ml, p < 0.0001) and vaspin (0.54 vs 0.31 ng/
ml, p = 0.015) levels. After adjustment for covariates (age and body mass index), patients with CRC had
signiﬁcantly higher serum omentin-1 (p < 0.0001), visfatin (p < 0.0001), and vaspin (p = 0.040) levels than
the control group. Furthermore, the results did not change when age and waist-to-hip ratio were consid-
ered as covariates in the general linear models.
Conclusions: The observed higher levels of omentin-1, visfatin, and vaspin in patients with CRC, indepen-
dent of measures of obesity, suggest that these adipocytokines may have a potential role in the develop-
ment of CRC through mechanisms other than the indirect mechanisms that are active in the association
between obesity and CRC.
 2013 Elsevier Ltd. All rights reserved.1. Introduction According to the International Agency for Cancer ResearchThe link between obesity and many human malignancies,
including colorectal cancer (CRC), has been clearly illustrated in
many epidemiological studies [1,2]. Overall, obese individuals are
approximately 1.5–2 times more at risk of developing gastrointes-
tinal cancers than normal weight individuals [1].ll rights reserved.
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).(IACR), there is sufﬁcient evidence in humans for a causal link be-
tween overweight and obesity and cancer of the colon [3]. How-
ever, the mechanistic basis of these relationships remains
incompletely understood.
Although the pathophysiological mechanisms underlying obes-
ity in relation to CRC are likely complex, increased insulin and
insulin-like growth factor signaling, intestinal microbiome, chronic
inﬂammation, and adipocytokines have already been postulated as
contributors.
Adipocytokines are protein factors that show a number of
important systemic complex interactions and inﬂuence a large
number of different organ systems [4]. They have recently become
the focus of research on the role of obesity in carcinogenesis. Sev-
eral adipocytokines, namely leptin, adiponectin, visfatin and resi-
stin, have been under investigation in a multitude of robust
in vitro and epidemiological studies carried out to clarify the asso-
ciation between obesity and CRC [5–12].
A decreased level of adiponectin was recognized as a strong risk
factor for early CRC [6]. Two types of adiponectin receptors,
82 M.S. Fazeli et al. / Cytokine 62 (2013) 81–85AdipoR1 and AdipoR2, may be intimately related to the progres-
sion of CRC [13]. Adiponectin can repress colon cancer cell
proliferation through AdipoR1- and –R2-mediated adenosin mono-
phosphate-activated protein kinase (AMPK) activation [14]. Under
decreased circulating adiponectin levels, AMPK activity is sup-
pressed, and the mammalian target of the rapamycin (mTOR)
and the members downstream in the pathway are activated. These
changes directly promote colonic epithelial cell proliferation and
induce colorectal carcinogenesis [15].
The results of a large case-control study suggested that adipo-
nectin might decrease the risk of colorectal neoplasia by interfering
with leptin; conversely, leptin could exert a carcinogenic effect un-
der the condition of a lower abundance of adiponectin [5]. There-
fore, the concurrent assessment of adiponectin and leptin may be
a helpful prognostic marker in the management of patients with
CRC [16].
Visfatin, which is identical to the ‘‘pre-B cell-colony enhancing
factor (PBEF1)’’ and ‘‘nicotinamide phosphoribosyltransferase
(Nampt),’’ is secreted abundantly by the visceral fat of humans
and mice and mimics the action of insulin [17]. There is accumulat-
ing evidence to support an interesting connection between PBEF1/
Nampt/Visfatin and cancer [18,19]. PBEF1/Nampt/Visfatin may
have pro-angiogenic activity, which is highly expressed in some
types of tumors, including malignant astrocytomas/glioblastomas,
ovarian cancers, gastric and CRC [20–23]. The results of a case-con-
trol study suggested that visfatin and resistin might be good bio-
markers of colorectal malignant potential and stage progression,
independent of the body mass index (BMI) [9].
Omentin-1 is a novel 34 kDa adipocytokine that is selectively
and highly expressed in visceral adipose tissue compared with sub-
cutaneous adipose tissue [4,24]. Vaspin (visceral adipose tissue-de-
rived serpin), a member of the serine protease inhibitor family, is
also a novel adipocytokine with insulin-sensitizing effects [25].
Against the background of previous research on the contribu-
tion of adipocytokines to the pathogenesis of CRC, investigating
the circulating levels of novel adipocytokines, such as omentin-1,
visfatin and vaspin may be useful to illustrate some pathophysio-
logical aspects of adipose tissue involvement in the development
of CRC. The present matched case-control study sought to explore
for the ﬁrst time the concentrations of serum omentin-1 and vas-
pin and assess visfatin levels in patients with CRC.2. Methods
2.1. Patients and controls
Thirty-nine consecutive new patients (mean age ± SD
56.72 ± 9.25 years: 23 women and 16 men) who had undergone
colonoscopy at Imam Khomeini University Hospital and had been
histopathologically diagnosed with CRC by hospital pathologists
were enrolled in the study in June 2008. All patients in the sample
met the following criteria: no curative medication for CRC; no pre-
vious history of malignancy or colorectal operations; no diagnosis
of any inﬂammatory bowel disease, including ulcerative colitis and
Crohn’s disease; no diagnosis of familial adenomatous polyposis or
acromegaly.
We selected a healthy age- and sex-matched control group
(mean age ± SD 53.03 ± 6.14 years: 15 women and 15 men) from
participants in the Persian Gulf Healthy Heart Study. The Persian
Gulf Healthy Heart Study, a prospective population based cohort
study, was designed to determine the risk factors for cardiovascu-
lar diseases among the northern Persian Gulf population. Detailed
information about the methods and procedures of this study is
available elsewhere [26].The participants in the control group had anthropometric mea-
surements comparable with those of the CRC group (Table 1).
Venous blood was obtained from all patients and healthy con-
trols in a fasting state. All the sera were kept frozen at 70 C until
they were used. The study was approved by the medical–ethical
committee of Bushehr University of Medical Sciences, and written
informed consent was obtained from all subjects.
2.2. Measurements
2.2.1. Physical measurements
Blood pressure was assessed twice at the right arm after a 15-
min rest in the sitting position, using a standard mercury
sphygmomanometer.
A stadiometer was used to measure height and weight. Heavy
outer garments and shoes were removed before the participants’
height and weight were measured. Body mass index (BMI) was cal-
culated. Waist circumference was deﬁned at the midway level be-
tween the costal margins and the iliac crests. Hip circumference
was measured at the level of the greater trochanters. Waist-to-
hip ratio (WHR) was calculated for all participants.
2.2.2. Biochemical measurements
A fasting blood sample was taken, all samples were promptly
centrifuged, and sera were separated and kept frozen at 70 C un-
til they were used. On the day of blood collection, analyses for bio-
chemical parameters (blood glucose, triglyceride, and cholesterol
levels) were carried out at the Persian Gulf Health Research Center
with a Selectra 2 autoanalyzer (Vital Scientiﬁc, Spankeren, the
Netherlands). Glucose was assayed by the enzymatic (glucose oxi-
dase) colorimetric method using a commercial kit (Pars Azmun
Inc., Tehran, Iran). Serum total cholesterol and HDL (high-density
lipoprotein) cholesterol were measured using cholesterol oxidase
phenol aminoantipyrine. Triglycerides were measured using the
glycerol-3 phosphate oxidase phenol aminoantipyrine enzymatic
method. Serum LDL (low-density lipoprotein) cholesterol was cal-
culated using the Friedwald formula. LDL cholesterol was not cal-
culated when the triglycerides concentration was >400 mg/dl.
To detect visfatin and vaspin in the serum samples, commer-
cially available (Cat. No. V0523EK and Cat. No. V0712EK, respec-
tively) enzyme-linked immunosorbent assay kits (AdipoGen,
Seoul, Korea) were used according to the manufacturer’s
instructions. The assay sensitivity for visfatin was 0.10 ng/ml; the
intra- and interassay coefﬁcients of variance were 3.8–5.5% and
6.4–9.5%, respectively. The assay sensitivity for vaspin was
0.012 ng/ml; the intra- and inter-assay coefﬁcients of variance
were 1.3–3.8% and 3.3–9.1%, respectively.
Serum omentin-1 concentrations were measured by manual
omentin-1 (human) detection (ELISA kit (intelectin-1 (human) ELI-
SA kit, Apotech Corporation, Switzerland)). The detection limit of
the assay was 0.4 ng/ml (range 0.5–32 ng/ml). The mean intraassay
and interassay CVs of the omentin-1 assay were 4.51–7.4% and
4.19–9.27%, respectively. The antibodies used in this kit are speciﬁc
to the measurement of natural and recombinant human omentin-
1.
2.3. Deﬁnitions
The cutoff points of serum total cholesterol (TC), high density
lipoprotein cholesterol (HDL-C), and low-density lipoprotein cho-
lesterol (LDL-C) distributions used to assign subjects to different
levels of risk were those derived from the National Cholesterol
Education Program (NCEP) guidelines in the United States (Adult
Treatment Panel [ATP] III) [27].
The tumor-node-metastasis (TNM) staging for colorectal cancer
deﬁned by the American Joint Committee on Cancer (AJCC), 7th
Table 1
The general characteristics, including blood pressure and anthropometric measure-
ments, and the biochemical parameters of patients with colorectal cancer (CRC) and
healthy controls.
Variables Colorectal group
(n = 39)
Control group
(n = 30)
p Value
Female/male ratio 23/16 15/15 0.458
Age (years) 56.72 ± 9.25 53.03 ± 6.14 0.064
SBP (mmHg) 118.82 ± 17.29 120.21 ± 14.85 0.732
DBP (mmHg) 75.66 ± 11.63 78.14 ± 9.40 0.357
WH ratio 0.94 ± 0.07 0.91 ± 0.08 0.163
BMI (kg/m2) 26.07 ± 4.58 27.15 ± 3.69 0.300
FBS (mg/dl) 137.48 ± 57.20 76.89 ± 20.37 <0.0001
Total cholesterols
(mg/dl)
221.61 ± 51.87 221.53 ± 43.89 0.407
Triglycerides (mg/dl) 131.00 ± 52.97 190.50 ± 117.38 0.007
HDL-C (mg/dl) 42.43 ± 14.48 42.83 ± 9.25 0.900
LDL-C (mg/dl) 153.12 ± 42.40 131.82 ± 30.00 0.026
DBP = diastolic blood pressure, FBS = fasting blood sugar, SBP = systolic blood
pressure
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2.4. Statistical analysis
Normal distribution of the data was controlled with the Kol-
mogorov–Smirnov test. Probability values <5% were considered
statistically signiﬁcant. The signiﬁcance of the difference in the re-
sults between the two groups was determined with chi-square
analysis using 2  2 contingency tables. A two-tailed t-test was
used to compare the values across groups.
We found that log transformation of circulating adipocytokines
gave a better ﬁt to a Gaussian distribution. The geometric mean for
those biochemical variables was deﬁned as the arithmetic mean of
the log-transformed data ±SD, raised to the power of 10.
With adjustment for age, partial correlation analysis was per-
formed to assess the association between circulating adipocyto-
kines levels and biochemical variables.
The general linear model (GLM) univariate procedure was used
for regression analysis and analysis of variance for adipocytokine
levels (as dependent variables) by the studied groups (as indepen-
dent variable). The covariates were age, BMI or WHR for GLM
models.
The generalized linear models were conducted to examine the
correlation between adipocytokines levels and the TNM staging
for colorectal cancer deﬁned by AJCC [28].
All statistical analyses were performed using the PASW Statis-
tics GradPack 18 (SPSS Inc., Chicago, IL).Fig. 1. Log transformed serum visfatin, vaspin and omentin-1 concentrations in
patients with colorectal cancer (CRC, n = 39) and healthy controls (n = 30). Data are
means ± standard deviation.3. Results
Table 1 shows the general characteristics, including blood pres-
sure, anthropometric measurements and biochemical parameters,
of patients with CRC (39 subjects) compared with the control
group (30 subjects). There were no signiﬁcant differences in age,
gender, systolic and diastolic blood pressure, WHR and BMI be-
tween the patients and the controls. There was also no signiﬁcant
difference in total cholesterol and HDL cholesterol between the
two groups. However, the CRC group had higher LDL cholesterol
and fasting blood glucose than the control group (p < 0.05, Table 1).
In contrast, the control group had higher serum triglyceride levels
than the CRC group (p < 0.05, Table 1).
Of the 69 participants, 2 (5.7%) and 3 (7.9%) subjects were
smokers in the patient and control groups, respectively (p > 0.05).
None of the participants had a history of alcohol consumption.There was no signiﬁcant difference in prevalence of the metabolic
syndrome between the patients and the controls (p > 0.05).
The results of the serum levels of the studied adipocytokines in
both groups are shown as geometric means (± standard deviation)
in Fig. 1. Compared with the controls, patients with CRC had signif-
icantly higher circulating visfatin, omentin-1 and vaspin levels
(p < 0.0001, p < 0.0001 and p = 0.015, respectively).
No gender differences were found for the circulating visfatin,
omentin-1 and vaspin (p > 0.05).
Age-adjusted correlations for serum visfatin, omentin-1 and
vaspin in relation to anthropometric and biochemical measures
were evaluated. Age-adjusted serum visfatin concentration levels
were marginally correlated with WHR in the CRC group (r = 0.33,
p = 0.045) and were signiﬁcantly correlated with serum triglycer-
ide (r = 0.42, p = 0.030) in the control group. However, there were
no signiﬁcant correlations between visfatin concentrations and
BMI, fasting blood glucose and other lipid proﬁle in both groups
(p > 0.05).
Age-adjusted serum omentin-1 concentration levels were sig-
niﬁcantly correlated with LDL cholesterol (r = 0.39, p = 0.014)
and total cholesterol levels (r = 0.404, p = 0.012) in patients with
CRC. However, there were no signiﬁcant correlations between
omentin-1 concentrations and BMI, WHR, and fasting blood glu-
cose in the CRC and control groups (p > 0.05).
Age-adjusted serum vaspin concentration levels were signiﬁ-
cantly correlated with fasting blood glucose (r = 0.36, p = 0.024)
in the CRC group. However, there were no signiﬁcant correlations
between vaspin concentrations and other biochemical and anthro-
pometric parameters in the patients with CRC and the controls
(p > 0.05).
Table 2 shows the unadjusted and adjusted geometric mean
±SD for circulating adipocytokines (visfatin, omentin-1 and vaspin)
levels stratiﬁed by the studied groups. After adjustment for covar-
iates (age and BMI), patients with CRC had signiﬁcantly higher ser-
um visfatin (p < 0.0001), omentin-1 (p < 0.0001) and vaspin
(p = 0.040) levels than the control group (Table 2). Furthermore,
the results did not change when age and waist-to-hip ratio were
considered covariates in the general linear models (Table 2).
The signiﬁcant differences in serum adipocytokines concentra-
tions between the patients with CRC and the controls did not also
change when the metabolic syndrome were considered as predic-
tor in the generalized linear models.
Among 30 patients with CRC; 2 cases were stage I, 9 cases were
stage IIA, 4 cases were stage IIB, 3 cases were stage IIIA, 5 cases
Table 2
Unadjusted and adjusted (age, BMI and WHR) circulating levels of adipocytokines in patients with colorectal cancer (CRC), compared with healthy controls.
Visfatin (ng/ml) Vaspin (ng/ml) Omentin-1 (ng/ml)
CRC Control p Value CRC Control p Value CRC Control p Value
Unadjusted 4.03 (1.72) 2.01 (2.16) <0.0001 0.54 (2.57) 0.31 (2.16) 0.015 203.23 (2.10) 9.12 (2.58) <0.0001
Age-, and BMI-adjusted 4.10 (1.72) 1.99 (2.18) <0.0001 0.55 (2.60) 0.30 (2.18) 0.025 202.76 (2.12) 8.95 (2.61) <0.0001
Age-, and WHR-adjusted 4.09 (1.73) 1.99 (2.18) <0.0001 1.79 (2.63) 0.30 (2.81) 0.027 201.37 (2.14) 8.95 (2.61) <0.0001
Data are geometric means (standard deviation).
BMI = body mass index, WHR = waist-to-hip ratio
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were no signiﬁcant correlations between circulating adipocytokine
levels and the TNM staging for colorectal cancer (p > 0.05).
4. Discussion
The patients with CRC had signiﬁcantly increased levels of visf-
atin, omentin-1 and vaspin compared with the control subjects.
The observed higher levels of these novel adipocytokines in the
CRC group were independent of measures of adiposity.
PBEF1 (PBEF1/Nampt/Visfatin) has been reported to be overex-
pressed in primary CRC [22,29]. Later, in agreement with our re-
sults, Nakajima et al. found that visfatin levels in patients with
CRC were signiﬁcantly higher than those of the controls [9].
PBEF1/Nampt/Visfatin is a multifactional protein that converts
nicotinamide to nicotinamide mononuclide, which is a key nicotin-
amide adenine dinucleotide (NAD) intermediate. PBEF1/Nampt/
Visfatin also functions as a cytokine and shows adipocytokine
activities [19]. These various functional aspects of PBEF1/Nampt/
Visfatin illustrate its potential role in linking NAD biology with
metabolism, inﬂammation and cancer [19,30].
The mechanisms by which PBEF1/Nampt/Visfatin-mediated
NAD biosynthesis inﬂuences carcinogenesis have not been discov-
ered. PBEF1/Nampt/Visfatin-mediated NAD biosynthesis is in-
volved in inﬂammation, cellular differentiation, and tumor
progression through downstream regulators such as sirtuins and
poly (ADP-ribose) polymerase (PARP). The sirtuins are known to
regulate both cell survival and tumor necrosis factor (TNF) secre-
tion [19,30].
More investigations on the PBEF1/Nampt/Visfatin-mediated
regulation of carcinogenesis through sirtuins are warranted in or-
der to clarify the underlying mechanisms of the association of visf-
atin with CRC, which was observed in our study.
Nakajima et al. reported gradually increased visfatin levels with
tumor progression [9]. However, we did not ﬁnd signiﬁcant corre-
lations between circulating adipocytokine levels and the TNM stag-
ing for colorectal cancer deﬁned by AJCC in generalized linear
models.
We did not ﬁnd a signiﬁcant correlation between visfatin levels
and BMI in either the CRC patients or the controls. The concentra-
tion of circulating visfatin in relation to obesity is controversial
[31–33]. In a recent study [34], PBEF1/Nampt/Visfatin mRNA levels
were not correlated with measures of obesity, and the researchers
suggested that visfatin is not predominantly secreted from visceral
fat.
Omentin-1 is a newly identiﬁed depot-speciﬁc adipocytokine in
human adipose tissue that enhances insulin action [24]; it is inver-
sely related to obesity [35] and is down regulated by insulin and
glucose [36].
Omentin-1 enhances Akt phosphorylation/activation in the ab-
sence and presence of insulin [25]. Novel data for the role of omen-
tin-1 in angiogenesis through the Akt signaling pathway has been
provided [37].
Akt kinases are not only vital for the regulation of essential cel-
lular functions, including proliferation, apoptosis, metabolism andtranscription, but also for the regulation of vascular permeability,
angiogenic responses and subsequent vascular maturation [38].
As neoangiogenesis and vascular leakage are important for angio-
genesis-dependent pathologies, Akt signaling is believed to play a
crucial role in carcinogenicity [39]. Itoh et al. showed that Akt acti-
vation plays an important role during the progression of CRC by
enhancement of cell proliferation activity and the blocking of
apoptosis [40]. In addition, endothelial nitric oxide synthase
(eNOS), a downstream target of Akt, has been shown to be impor-
tant in tumorigenesis, including colorectal carcinogenesis [41,42].
The eNOS polymorphisms in relation to colorectal cancer risk were
also investigated [42].
The Akt cascade is activated by stimuli that induce the produc-
tion of phosphatidylinositol 3,4,5 triphosphates by phosphoinosi-
tide 3-kinase (PI3K) [43]. Lim et al. suggested that the activation
of PI3K/Akt-eNos signaling transduction is required during initia-
tion and maintenance of oncogenic Ras-driven tumour growth
[41]. Ras-gene mutations were found in 58% of colonic adenomas
larger than 1 cm and in 47% of CRC [44].
Thus, there is sufﬁcient evidence that the PI3K/Akt-eNos Ras
pathway may be involved in colorectal-tumor development. Since
omentin-1 enhances Akt phosphorylation/activation [24], it can be
hypothesized that omentin-1, by promoting activation of the Akt
signaling pathway and in turn modulating eNOS, may contribute
in the pathogenesis of CRC.
Vaspin (visceral adipose tissue-derived serine protease inhibi-
tor), a recently identiﬁed adipocytokine, has been suggested to
have an insulin-sensitizing effect [25]. The circulating levels and
tissue expression of vaspin increased at the peak of obesity and
insulin resistance in Otsuka Long-Evans Tokushima fatty (OLETF)
rats, an animal model of abdominal obesity and type 2 diabetes
mellitus [45]. In the current study, for the ﬁrst time, we found that
patients with CRC had higher circulating levels of vaspin, in com-
parison with the controls. Thus, similar to omentin-1, vaspin may
also be involved in carcinogenicity. However, the exact mechanism
underlying vaspin in relation to cancer growth remains to be
elucidated. Recently, Jung et al. [46] reported that vaspin protects
vascular endothelial cells against free fatty acid-induced apoptosis
through upregulation of the PI3K/Akt signaling pathway. There-
fore, it can be hypothesized that vaspin may affect the PI3K/Akt
pathway, produce cell proliferation activity, and prevent apoptosis.
We acknowledge several limitations in our study. A major
limitation is the study’s cross-sectional nature. Thus, limited
inferences can be made regarding causality. Since we assessed
the investigated adipocytokines with single measurements, the
changes in these adipocytokines over time could not be reﬂected
in the current study. The sample size was small, which may have
affected our statistical power. In the current study, indices of insu-
lin resistance were not measured. Another limitation of our study
includes the lack of the TNM staging information for approxi-
mately one fourth of patients with CRC. Some novel adipocytokines
were reported to be good biomarkers of the stage progression of
CRC [9]. The measurement of additional adipocytokines and
inﬂammatory markers and cytokines merits consideration in order
to elucidate the ‘‘adipocytokines and cancer complex system’’.
M.S. Fazeli et al. / Cytokine 62 (2013) 81–85 85In conclusion, circulating visfatin, omentin-1 and vaspin levels
differed signiﬁcantly between the patients with CRC and the con-
trols. The association of higher levels of these novel adipocytokines
with CRC remained after further adjustment for BMI or WHR. Our
ﬁndings suggest that these adipocytokines may have a potential
role in the development of CRC through mechanisms other than
the indirect mechanisms that are active in the association of obes-
ity and CRC. Integrative pathophysiological approaches are war-
ranted to clarify this intermingled ‘‘adipocytokines and cancer
complex system’’. The elucidation of this complex system will
undoubtedly produce promising and novel pharmacological in-
sights for treatment of CRC in the future.
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